The Food and Drug Administration (FDA) granted the first emergency use authorization for an antibody treatment for COVID-19 from pharmacist Eli Lilly.
The investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg, which is licensed for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years of age and older with a positive COVID-19 test and may complicate their situation.
The FDA has granted its first Emergency Use Authorization for a #covid19 antibody treatment: Eli Lily’s monoclonal bamlanivimab (LY-CoV555).
— Dr Alexandra Phelan (@alexandraphelan) November 10, 2020
The US has purchased 300,000 doses for high risk patients, with no out of pocket costs for the medicine itself.https://t.co/A2dN4vZdcD
According to a pharmacist’s statement, bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within ten days of symptoms onset.
“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for newly diagnosed high-risk patients, adding a valuable tool for physicians struggling with the now growing burden of this global pandemic,” David A. Ricks, Lilly president, and CEO said in the statement.
